A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 979-988

  Wilson, Peter M ^a   El Khoueiry, Anthony ^a   Iqbal, Syma ^a   Fazzone, William ^a   Labonte, Melissa J ^a   Groshen, Susan ^a   Yang, Dongyun ^a   Danenberg, Kathy D ^b   Cole, Sarah ^a   Kornacki, Margaret ^a   Ladner, Robert D ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Response Genetics Inc   (United States)

Author keywords

5 Fluorouracil; Colon; HDACi; Phase I; Thymidylate synthase

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HISTONE H3; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PANITUMUMAB; THYMIDYLATE SYNTHASE; VORINOSTAT;

ABDOMINAL PAIN; ACETYLATION; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; LASER CAPTURE MICRODISSECTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HISTONE ACETYLTRANSFERASES; HUMANS; HYDROXAMIC ACIDS; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TREATMENT FAILURE;

EID: 77649183822     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1236-x     Document Type: Article

References (45)

1. S Giacchetti B Perpoint R Zidani N Le Bail R Faggiuolo C Focan, et al. 2000 Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 136 147 10623704
2. JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 10.1016/S0140-6736(00)02034-1 10744089
3. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 10.1200/JCO.2006.09.6305 17442997 (Pubitemid 46733080)
4. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 15175435 (Pubitemid 38702844)
5. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
6. HJ Lenz E Van Cutsem S Khambata-Ford RJ Mayer P Gold P Stella, et al. 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 4914 4921 10.1200/JCO.2006.06.7595 17050875 (Pubitemid 46630920)
7. DB Longley DP Harkin PG Johnston 2003 5-Fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330 338 10.1038/nrc1074 12724731 (Pubitemid 37328853)
8. T Inoue K Hibi G Nakayama Y Komatsu T Fukuoka Y Kodera, et al. 2005 Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer J Gastroenterol 40 143 147 10.1007/s00535-004-1512-9 15770397 (Pubitemid 40425201)
9. PG Johnston HJ Lenz CG Leichman KD Danenberg CJ Allegra PV Danenberg, et al. 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407 1412 7882343
10. Y Shirota J Stoehlmacher J Brabender YP Xiong H Uetake KD Danenberg, et al. 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 4298 4304 11731512
11. S Popat A Matakidou RS Houlston 2004 Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis J Clin Oncol 22 529 536 10.1200/JCO.2004.05.064 14752076 (Pubitemid 41079782)
12. P Bali M Pranpat J Bradner M Balasis W Fiskus F Guo, et al. 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 26729 26734 10.1074/jbc. C500186200 15937340 (Pubitemid 41040705)
13. MA Glozak N Sengupta X Zhang E Seto 2005 Acetylation and deacetylation of non-histone proteins Gene 363 15 23 10.1016/j.gene.2005.09.010 16289629 (Pubitemid 41691888)
14. C Hubbert A Guardiola R Shao Y Kawaguchi A Ito A Nixon, et al. 2002 HDAC6 is a microtubule-associated deacetylase Nature 417 455 458 10.1038/417455a 12024216 (Pubitemid 34563539)
15. DC Drummond CO Noble DB Kirpotin Z Guo GK Scott CC Benz 2005 Clinical development of histone deacetylase inhibitors as anticancer agents Annu Rev Pharmacol Toxicol 45 495 528 10.1146/annurev.pharmtox.45.120403.095825 15822187 (Pubitemid 40261815)
16. VM Richon S Emiliani E Verdin Y Webb R Breslow RA Rifkind, et al. 1998 A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc Natl Acad Sci U S A 95 3003 3007 10.1073/pnas.95.6. 3003 9501205 (Pubitemid 28135844)
17. VM Richon J Garcia-Vargas JS Hardwick 2009 Development of vorinostat: current applications and future perspectives for cancer therapy Cancer Lett 280 201 210 10.1016/j.canlet.2009.01.002 19181442
18. BS Mann JR Johnson MH Cohen R Justice R Pazdur 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247 1252 10.1634/theoncologist.12-10-1247 17962618 (Pubitemid 350106355)
19. W Zhang M Peyton Y Xie J Soh JD Minna AF Gazdar, et al. 2009 Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines J Thorac Oncol 4 161 166 10.1097/JTO.0b013e318194fae7 19179890
20. QL Zhang L Wang YW Zhang XX Jiang F Yang WL Wu, et al. 2009 The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 1507 1514 10.1038/leu.2009.41 19282831
21. A Tumber LS Collins KD Petersen A Thougaard SJ Christiansen M Dejligbjerg, et al. 2007 The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo Cancer Chemother Pharmacol 60 275 283 10.1007/s00280-006-0374-7 17124594 (Pubitemid 46742543)
22. JH Lee JH Park Y Jung JH Kim HS Jong TY Kim, et al. 2006 Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol Cancer Ther 5 3085 3095 10.1158/1535-7163.MCT-06-0419 17172411 (Pubitemid 46092050)
23. WG Zhu GA Otterson 2003 The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells Curr Med Chem Anti-Cancer Agents 3 187 199 10.2174/1568011033482440 (Pubitemid 36512029)
24. R Nimmanapalli L Fuino C Stobaugh V Richon K Bhalla 2003 Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood 101 3236 3239 10.1182/blood-2002-08-2675 12446442 (Pubitemid 36858020)
25. L Fuino P Bali S Wittmann S Donapaty F Guo H Yamaguchi, et al. 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984 14578462
26. TM Pitts M Morrow SA Kaufman JJ Tentler SG Eckhardt 2009 Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models Mol Cancer Ther 8 342 349 10.1158/1535-7163.MCT-08-0534 19174560
27. W Fazzone PM Wilson MJ Labonte HJ Lenz RD Ladner 2009 Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells Int J Cancer 125 463 473 10.1002/ijc.24403 19384949
28. KB Glaser MJ Staver JF Waring J Stender RG Ulrich SK Davidsen 2003 Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2 151 163 12589032
29. VM Richon TW Sandhoff RA Rifkind PA Marks 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci U S A 97 10014 10019 10.1073/pnas.180316197 10954755
30. MJ Labonte PM Wilson W Fazzone S Groshen HJ Lenz RD Ladner 2009 DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines BMC Med Genomics 2 67 10.1186/1755-8794-2-67 19948057
31. CG Leichman HJ Lenz L Leichman K Danenberg J Baranda S Groshen, et al. 1997 Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 3223 3229 9336359
32. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S et al. (1997) Laser capture microdissection: molecular analysis of tissue. Science 278:1481, 1483
33. M Azuma M Shi KD Danenberg H Gardner C Barrett CJ Jacques, et al. 2007 Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients Pharmacogenomics 8 1705 1713 10.2217/14622416.8.12.1705 18086000
34. CG Leichman HJ Lenz L Leichman K Danenberg J Baranda S Groshen, et al. 1997 Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 3223 3229 9336359
35. RV Lord D Salonga KD Danenberg JH Peters TR DeMeester JM Park, et al. 2000 Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence J Gastrointest Surg 4 135 142 10.1016/S1091-255X(00)80049-9 10675236
36. SE Koehler RD Ladner 2004 Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition Mol Pharmacol 66 620 626 15322254
37. PM Wilson W Fazzone MJ LaBonte J Deng N Neamati RD Ladner 2008 Novel opportunities for thymidylate metabolism as a therapeutic target Mol Cancer Ther 7 3029 3037 10.1158/1535-7163.MCT-08-0280 18790783
38. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M et al (2009) A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. J Clin Oncol 27:15 s (suppl; abstr 4083)
39. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan, et al. 2003 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059 2069 10.1200/JCO.2003.11.126 12775730 (Pubitemid 46606353)
40. MG Fakih L Pendyala G Fetterly K Toth JA Zwiebel I Espinoza-Delgado, et al. 2009 A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer Clin Cancer Res 15 3189 3195 10.1158/1078-0432.CCR- 08-2999 19383814
41. WK Kelly OA O'Connor LM Krug JH Chiao M Heaney T Curley, et al. 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 3923 3931 10.1200/JCO.2005.14.167 15897550 (Pubitemid 46218695)
42. WK Kelly VM Richon O O'Connor T Curley B MacGregor-Curtelli W Tong, et al. 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 3578 3588 14506144
43. PA Marks R Breslow 2007 Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 25 84 90 10.1038/nbt1272 17211407 (Pubitemid 46087907)
44. N Khan M Jeffers S Kumar C Hackett F Boldog N Khramtsov, et al. 2008 Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem J 409 581 589 10.1042/BJ20070779 17868033 (Pubitemid 351184977)
45. F Giles T Fischer J Cortes G Garcia-Manero J Beck F Ravandi, et al. 2006 A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 12 4628 4635 10.1158/1078-0432.CCR-06-0511 16899611 (Pubitemid 44297814)